16th Apr 2013 12:24
NOTIFICATION OF TRANSACTIONS OF DIRECTORS AND APPLICABLE EMPLOYEES
VERNALIS PLC (the "Company")
16 April 2013
Vernalis plc (LSE: VER) announces that on 15 April 2013, in accordance with the rules of the 2012 Value Builder Plan, the following options over the Company's ordinary shares, with a nominal value of 1 pence each, were granted to the Executive Directors and certain members of the management committee (who are "Applicable Employees" for the purposes of the AIM Rules for Companies):
Executive Director | No of shares under option | Exercise Price | % of Issued Share Capital |
Ian Garland | 3,105,912 | 1 pence | 0.703% |
David Mackney | 2,162,977 | 1 pence | 0.489% |
Applicable Employees | No of shares under option | Exercise Price | % of Issued Share Capital |
Mike Wood | 637,043 | 1 pence | 0.144 % |
Stephen Pawsey | 549,209 | 1 pence | 0.124% |
The options are exercisable five years following grant provided that the performance conditions of the option scheme are met.
Enquiries:
Vernalis | +44 (0) 118 938 0015 |
Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer
| |
Nomura Code Securities Limited | +44 (0) 20 7776 1200 |
Juliet Thompson Jonathan Senior
| |
Brunswick Group | +44 (0) 20 7404 5959 |
Jon Coles
|
Notes to Editors
About Vernalis
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough/cold market as well as seven programmes in its NCE development pipeline. Vernalis has significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.
For further information about Vernalis, please visit www.vernalis.com
Related Shares:
Vernalis PLC